Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT) A Randomized, Double-Blind, Placebo-Controlled Trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A73598555" target="_blank" >RIV/61989592:15110/11:73598555 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/11:00055476 RIV/61988987:17110/11:A12014HT RIV/00098892:_____/11:N0000001

Výsledek na webu

<a href="https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.111.169961" target="_blank" >https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.111.169961</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961" target="_blank" >10.1161/HYPERTENSIONAHA.111.169961</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT) A Randomized, Double-Blind, Placebo-Controlled Trial

Popis výsledku v původním jazyce

There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP &gt; 140 mm Hg or diastolic BP &gt; 90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n = 59) or a placebo (n = 58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was -5.4 mm Hg (95% CI -10.0; -0.8) for systolic BP (P = 0.024) and -1.0 mm Hg (95% CI -4.0; 2.0) for diastolic BP (P = 0.358). The APBM nighttime systolic, 24-hour ABPM systolic, and office systolic BP values were significantly decreased by spironolactone (difference of -8.6, -9.8, and -6.5 mm Hg; P = 0.011, 0.004, and 0.011), whereas the fall of the respective diastolic BP values was not significant (-3.0, -1.0, and -2.5 mm Hg; P = 0.079, 0.405, and 0.079). The adverse events in both groups were comparable. In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension. (Hypertension. 2011;57:1069-1075.). Online Data Supplement

Název v anglickém jazyce

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT) A Randomized, Double-Blind, Placebo-Controlled Trial

Popis výsledku anglicky

There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP &gt; 140 mm Hg or diastolic BP &gt; 90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n = 59) or a placebo (n = 58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was -5.4 mm Hg (95% CI -10.0; -0.8) for systolic BP (P = 0.024) and -1.0 mm Hg (95% CI -4.0; 2.0) for diastolic BP (P = 0.358). The APBM nighttime systolic, 24-hour ABPM systolic, and office systolic BP values were significantly decreased by spironolactone (difference of -8.6, -9.8, and -6.5 mm Hg; P = 0.011, 0.004, and 0.011), whereas the fall of the respective diastolic BP values was not significant (-3.0, -1.0, and -2.5 mm Hg; P = 0.079, 0.405, and 0.079). The adverse events in both groups were comparable. In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension. (Hypertension. 2011;57:1069-1075.). Online Data Supplement

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

HYPERTENSION

ISSN

0194-911X

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

1069-1075

Kód UT WoS článku

000290710800017

EID výsledku v databázi Scopus

2-s2.0-79956349197